SEC Filings
Dyne Spends $161.7 Million On Research As It Prepares For A Potential Drug Launch
The quarterly loss widened to $193.6 million, with manufacturing, late-stage trials and launch preparations driving higher costs.
Dyne Therapeutics (DYN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The quarterly loss widened to $193.6 million, with manufacturing, late-stage trials and launch preparations driving higher costs.
SEC Filings
Z-basivarsen cut hand-opening time by 3.2 seconds at six months and diverged from a natural history control group at 12 months across four measures.